EXELEXELIXIS, INC.
Biological Products, (no Diagnostic Substances)
- Revenue
- $2.3B
- 7.0% YoY
- Operating margin
- 37.6%
- 35% YoY
- EBITDA
- $901M
- 42% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -0.3×
- −$305M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear113% of net incomeCash flow under 80% of net income
- Dilutive SBCClear5% of revenueOver 10% of revenue
- Payouts exceed cash flowFired107% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear3% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2022 | FY2023 | FY2025 | FY2026 | YoY |
|---|---|---|---|---|---|
| Revenue | $1.6B | $1.8B | $2.2B | $2.3B | 7.0% |
| Operating income | $201M | $171M | $605M | $872M | 44% |
| Net income | $182M | $208M | $521M | $783M | 50% |
| Operating cash flow | $363M | $333M | $700M | $884M | 26% |
| Capex | $28M | $40M | $28M | $8M | 70% |
| Stock-based comp | $108M | $106M | $94M | $113M | 20% |
| Buybacks | $0 | $550M | $652M | $948M | 45% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $2M · 1
- Net
- −$2M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2026 | $33M | $55M | 217 | 125 |
| FY2025 | $13M | $39M | 200 | 122 |
| FY2023 | $16M | $32M | 141 | 121 |
| FY2022 | $17M | $16M | 94 | 116 |
| FY2021 | $8M | $15M | 107 | 129 |